{"product_id":"ymab-vrio-analysis","title":"Y-mAbs Therapeutics, Inc. (YMAB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eReady to uncover the secrets behind Y-mAbs Therapeutics, Inc. (YMAB)'s market standing? This concise VRIO analysis cuts straight to the chase, evaluating if its core assets are truly Valuable, Rare, Inimitable, and Organized enough to secure a lasting competitive advantage. Dive in below to see the distilled summary of its true strategic reality and what it means for its future success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eY-mAbs Therapeutics, Inc. (YMAB) - VRIO Analysis: 1. DANYELZA Commercial Product (Naxitamab-gqgk)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core revenue driver for Y-mAbs Therapeutics, Inc. right now, DANYELZA. It’s the company’s ticket to being a commercial-stage player, but its long-term strength depends on how well the organization supports it while the pipeline matures. Let’s break down its competitive position using the VRIO lens.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Immediate Revenue Stream\u003c\/h3\u003e\n\u003cp\u003eDANYELZA provides immediate, recognized revenue, which is crucial for any development-stage biotech. For the first quarter of fiscal year 2025, net product revenues hit \u003cstrong\u003e$20.9 million\u003c\/strong\u003e. This is a solid start to the year, building on the full year 2024 total revenues of \u003cstrong\u003e$87.7 million\u003c\/strong\u003e. That number establishes them as a company with a product in the market, not just a promise on a slide. It’s real money funding the next steps. That’s the value right there.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: First-Mover Status in a Niche\u003c\/h3\u003e\n\u003cp\u003eThe rarity here is nuanced. While other GD2-targeting therapies exist, like Unituxin and Qarziba, DANYELZA holds the distinction of being the first FDA-approved treatment for this specific indication: relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease. That specific regulatory win gives it a unique, albeit potentially temporary, market slot. It’s not entirely unique, but its specific approval status is rare.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Regulatory Moat and Patent Life\u003c\/h3\u003e\n\u003cp\u003eHonestly, copying an approved oncology drug isn’t a weekend project. The regulatory hurdles and the established, validated supply chain for an approved cancer therapy are difficult and expensive for a competitor to replicate quickly. Plus, Y-mAbs secured an extension of the primary U.S. patent for DANYELZA, which now remains in effect until February 2034. That patent protection is a significant barrier to direct imitation for the next decade or so. It buys them time, which is priceless in this industry.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Dedicated Focus and Leadership\u003c\/h3\u003e\n\u003cp\u003eThe company recognized the need to maximize this asset, so they realigned operations in January 2025, splitting into two dedicated business units: Radiopharmaceuticals and DANYELZA. They put Doug Gentilcore, an executive with extensive commercialization experience, in charge of the DANYELZA business unit to push sales beyond the \u003cstrong\u003e$87.7 million\u003c\/strong\u003e achieved in 2024. This structural change shows they are organized to exploit the commercial opportunity, but the organization’s overall stability - especially following prior workforce adjustments - is still something to watch. Here’s the quick math: a dedicated unit should improve focus, but execution risk remains high.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Scoring\u003c\/h3\u003e\n\u003cp\u003eBased on the VRIO dimensions, here is how DANYELZA currently stacks up as a competitive advantage for Y-mAbs Therapeutics, Inc.:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eCompetitive Implication\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes (\u003cstrong\u003e$20.9 million\u003c\/strong\u003e Q1 2025 Revenue)\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity \/ Temporary Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eModerate (First-in-class for specific indication)\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eDifficult (Regulatory approval, Patent to 2034)\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eModerate (New dedicated business unit)\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is that the advantage is only \u003cstrong\u003eTemporary\u003c\/strong\u003e. While protected now by patents and regulatory status, that exclusivity window will eventually close, making the success of their next-generation pipeline - like the SADA PRIT platform - absolutely critical for sustained advantage.\u003c\/p\u003e\n\u003cp\u003eYou should review the Q2 2025 revenue guidance, which management set between \u003cstrong\u003e$17 million\u003c\/strong\u003e and \u003cstrong\u003e$19 million\u003c\/strong\u003e, against actual performance to gauge the effectiveness of the new DANYELZA business unit structure. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eY-mAbs Therapeutics, Inc. (YMAB) - VRIO Analysis: 2. SADA PRIT Technology Platform (Self-Assembly DisAssembly Pretargeted Radioimmunotherapy)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers a potential step-change in radioimmunotherapy by aiming for high tumor dose with lower off-target exposure, which is a huge plus for patient safety.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. This specific pre-targeting mechanism is quite novel in the current landscape.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Competitors are actively developing similar targeted delivery methods, though the specific construct is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are actively advancing it, dosing the first patient in Trial 1201 (NHL) in Q1 2025 and gathering data from the GD2-SADA Phase 1 trial.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. If proven superior in late-stage trials, this platform technology could become a durable, platform-level advantage.\u003c\/p\u003e\n\u003cp\u003eThe platform's advancement is supported by ongoing clinical activities and preclinical data demonstrating favorable dosimetry:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eTrial 1001 (GD2-SADA)\u003c\/th\u003e\n\u003cth\u003eTrial 1201 (CD38-SADA)\u003c\/th\u003e\n\u003cth\u003ePreclinical Data (Example)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatus\/Cohort\u003c\/td\u003e\n\u003ctd\u003ePart A Completed\u003c\/td\u003e\n\u003ctd\u003eDosing Initiated\u003c\/td\u003e\n\u003ctd\u003eNeuroblastoma PDX Ablation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Dosed (to date)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eFirst patient dosed in \u003cstrong\u003eQ1 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5\/5\u003c\/strong\u003e mice showed complete response\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety Finding\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNo DLTs\u003c\/strong\u003e reported in Part A\u003c\/td\u003e\n\u003ctd\u003eInformed by $\\text{20X}$ faster monomer clearance\u003c\/td\u003e\n\u003ctd\u003eKidneys\/Blood absorbed dose: \u003cstrong\u003e191 cGy\u003c\/strong\u003e \/ \u003cstrong\u003e44 cGy\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor Dose (Example)\u003c\/td\u003e\n\u003ctd\u003eValidated positive tumor uptake with $\\text{30 mCi}$ $\\text{Lu-DOTA}$\u003c\/td\u003e\n\u003ctd\u003eUtilizes $\\text{Lu177-DOTA}$ payload\u003c\/td\u003e\n\u003ctd\u003eTumor absorbed dose: \u003cstrong\u003e5,000 cGy\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial and organizational milestones relevant to platform advancement include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePreliminary estimated unaudited full year 2024 total net revenue of approximately \u003cstrong\u003e\\$88 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePreliminary estimated cash, cash equivalents and marketable securities as of December 31, 2024, of approximately \u003cstrong\u003e\\$67 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFirst Quarter 2025 Net Product Revenues reported as \u003cstrong\u003e\\$20.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFirst Quarter 2025 Net Loss of \u003cstrong\u003e\\$5.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe SADA technology is exclusively licensed from Memorial Sloan Kettering Cancer Center (MSK), which holds institutional financial interests in the technology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eY-mAbs Therapeutics, Inc. (YMAB) - VRIO Analysis: 3. High Gross Margins on Product Sales\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nStrong profitability on sales, with gross margins holding at \u003cstrong\u003e86%\u003c\/strong\u003e for the six months ended June 30, \u003cstrong\u003e2025\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate. High margins are common for specialized biologics, but maintaining them amid supply chain shifts is key.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate. Competitors can achieve similar margins, but only if they master the complex manufacturing process.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nConsistent margin performance demonstrates effective cost control within the DANYELZA supply chain, despite gross margin pressure in Western Europe sales noted in H1 \u003cstrong\u003e2025\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. It depends on maintaining manufacturing efficiency and avoiding unexpected cost increases.\n\u003c\/p\u003e\n\u003cp\u003e\nFinancial metrics related to gross margin performance for the six months ended June 30 are presented below:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eSix Months Ended June 30, 2025\u003c\/th\u003e\n\u003cth\u003eSix Months Ended June 30, 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$34.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$37.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of Goods Sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e86%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e88%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe gross margin decrease for the six months ended June 30, \u003cstrong\u003e2025\u003c\/strong\u003e, to \u003cstrong\u003e86%\u003c\/strong\u003e from \u003cstrong\u003e88%\u003c\/strong\u003e in the prior year period was primarily due to increased cost of production and lower product sales to Western Europe, where product sales generally have higher gross margin.\n\u003c\/p\u003e\n\u003cp\u003e\nKey revenue components for the second quarter of \u003cstrong\u003e2025\u003c\/strong\u003e:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. DANYELZA net product revenues: \u003cstrong\u003e$14.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEx-U.S. DANYELZA net product revenues: \u003cstrong\u003e$4.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Revenues: \u003cstrong\u003e$19.5 million\u003c\/strong\u003e, exceeding guidance of between $17 million and $19 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eY-mAbs Therapeutics, Inc. (YMAB) - VRIO Analysis: 4. Regulatory \u0026amp; Guideline Endorsement for DANYELZA\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Inclusion in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroblastoma drives physician adoption and reimbursement certainty. This endorsement is based on clinical efficacy data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStudy 201 Overall Response Rate (ORR): \u003cstrong\u003e45%\u003c\/strong\u003e (n=22)\u003c\/li\u003e\n\u003cli\u003eStudy 201 6-month Duration of Response (DOR): \u003cstrong\u003e30%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eStudy 12-230 ORR: \u003cstrong\u003e34%\u003c\/strong\u003e (n=38)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Guideline inclusion is a major hurdle that many drugs fail to clear. DANYELZA received accelerated FDA approval in \u003cstrong\u003eNovember 2020\u003c\/strong\u003e, with NCCN inclusion as a Category 2A option occurring around May 2025, representing a time lag of approximately \u003cstrong\u003e4.5 years\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. It requires successful clinical data and payer acceptance, which takes years.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The commercial team is structured to capitalize on this endorsement for growth outside the initial center. Recent operational metrics demonstrate market penetration:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDANYELZA net product revenues for Q1 2025: \u003cstrong\u003e$20.9 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eU.S. net product revenues for Q1 2025: \u003cstrong\u003e$13.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eEx-U.S. DANYELZA net product revenues for Q1 2025: \u003cstrong\u003e$7.5 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAs of March 31, 2025, DANYELZA delivered to \u003cstrong\u003e70\u003c\/strong\u003e centers across the U.S. since launch\u003c\/li\u003e\n\u003cli\u003eIn Q1 2025, approximately \u003cstrong\u003e72%\u003c\/strong\u003e of U.S. vials sold were outside of Memorial Sloan Kettering Cancer Center, up from \u003cstrong\u003e64%\u003c\/strong\u003e in Q4 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. NCCN inclusion acts as a strong barrier to entry for new competitors in the near term. The NCCN designation is a \u003cstrong\u003eCategory 2A\u003c\/strong\u003e recommendation.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eValue\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Status\u003c\/td\u003e\n\u003ctd\u003eFDA Accelerated Approval Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 25, 2020\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Status\u003c\/td\u003e\n\u003ctd\u003eNCCN Guideline Recommendation Status\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCategory 2A\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Efficacy (Study 201)\u003c\/td\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Efficacy (Study 12-230)\u003c\/td\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e34%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Performance (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003eTotal DANYELZA Net Product Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Organization (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003eU.S. Centers Delivered To (Cumulative as of 3\/31\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e70\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eY-mAbs Therapeutics, Inc. (YMAB) - VRIO Analysis: 5. Cash Position and Financial Runway\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Approximately \u003cstrong\u003e$62.3 million\u003c\/strong\u003e in cash and cash equivalents as of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e. This position, combined with anticipated product revenues, is expected to fund operations as currently planned into \u003cstrong\u003e2027\u003c\/strong\u003e based on the current business plan.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The cash position provides stability for Research and Development execution, contrasting with many small biotechs facing immediate liquidity constraints. The cash position decreased from \u003cstrong\u003e$67.2 million\u003c\/strong\u003e at December 31, 2024 to \u003cstrong\u003e$60.3 million\u003c\/strong\u003e at March 31, 2025, before reaching \u003cstrong\u003e$62.3 million\u003c\/strong\u003e by June 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Cash is a fungible resource. The capital efficiency demonstrated by operating below anticipated 2025 cash investment guidance of between \u003cstrong\u003e$25 million\u003c\/strong\u003e and \u003cstrong\u003e$30 million\u003c\/strong\u003e is a management practice, not an inimitable resource itself. The Total Annual Cash Investment in 2024 was \u003cstrong\u003e$11.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management has demonstrated focus on capital efficiency, as evidenced by the actual 2024 cash investment of \u003cstrong\u003e$11.4 million\u003c\/strong\u003e being favorable relative to guidance, and operating below the 2025 guidance in Q1 2025. However, the pending acquisition by SERB Pharmaceuticals for an equity value of \u003cstrong\u003e$412.0 million\u003c\/strong\u003e suggests a strategic shift or culmination of organizational efforts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a finite resource that will be depleted without new financing or sustained product revenue growth. Second quarter 2025 Total Revenues were \u003cstrong\u003e$19.5 million\u003c\/strong\u003e, resulting in a net loss of \u003cstrong\u003e$3.2 million\u003c\/strong\u003e, or \u003cstrong\u003e($0.07)\u003c\/strong\u003e per basic and diluted share for the quarter ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eFinancial Metrics Comparison:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$62.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Funding Runway\u003c\/td\u003e\n\u003ctd\u003eCurrent Plan\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPS (Basic \u0026amp; Diluted)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($0.07)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Annual Cash Investment Guidance\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e$25 million\u003c\/strong\u003e and \u003cstrong\u003e$30 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Annual Cash Investment (Actual)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey Financial Operational Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Danyelza Product Revenues for Q1 2025: \u003cstrong\u003e$20.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDanyelza Segment Profit Margin for Q1 2025: \u003cstrong\u003e42%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross Margin for the six months ended June 30, 2025: \u003cstrong\u003e86%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePending Acquisition Offer Price Per Share: \u003cstrong\u003e$8.60\u003c\/strong\u003e in cash.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eY-mAbs Therapeutics, Inc. (YMAB) - VRIO Analysis: 6. Y-BiClone Platform for Bispecific Antibodies\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a proprietary method for generating bispecific antibodies, broadening the company’s therapeutic modality beyond just radioimmunotherapy.\u003c\/p\u003e\n\u003cp\u003eThe platform supports the development of candidates such as the bispecific GD2 antibody, for which the US FDA cleared the Investigational New Drug (IND) application. The company's total Research and development expenses for the year ended December 31, 2024, were \u003cstrong\u003e$49.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many firms use bispecific tech, but the specific Y-BiClone generation method is proprietary.\u003c\/p\u003e\n\u003cp\u003eThe proprietary nature is evidenced by the specific design of the bispecific GD2 antibody, which is a fully humanized IgG-scFv format antibody with an Fc region mutation designed to prevent cytokine release.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can develop their own bispecific platforms, but YMAB has a head start in applying it.\u003c\/p\u003e\n\u003cp\u003eThe platform has progressed at least one candidate into clinical trials, as indicated by the IND clearance for the bispecific GD2 antibody.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. It’s part of the overall R\u0026amp;D engine, though less publicly highlighted than SADA PRIT in early 2025 updates.\u003c\/p\u003e\n\u003cp\u003eThe company's organizational focus has shifted resources, as the CD33 bispecific antibody construct was deprioritized as part of a restructuring plan announced in January 2023. The R\u0026amp;D investment for the nine months ended September 30, 2024, totaled \u003cstrong\u003e$36.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A proprietary platform technology offers long-term potential for multiple future drug candidates.\u003c\/p\u003e\n\u003cp\u003eThe platform's output is part of the company's advanced product pipeline. The following table outlines known assets associated with the company's antibody technologies, including those leveraging the Y-BiClone platform:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology\/Platform\u003c\/td\u003e\n\u003ctd\u003eAsset Name\u003c\/td\u003e\n\u003ctd\u003eTarget\/Indication\u003c\/td\u003e\n\u003ctd\u003eStatus\/Note\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eY-BiClone\u003c\/td\u003e\n\u003ctd\u003eBispecific GD2 Antibody\u003c\/td\u003e\n\u003ctd\u003eRelapsed\/Refractory Neuroblastoma, High-Grade Osteosarcoma, GD2(+) Solid Tumors\u003c\/td\u003e\n\u003ctd\u003eIND Cleared for Phase 1\/2 Trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eY-BiClone\u003c\/td\u003e\n\u003ctd\u003eCD33 Bispecific Antibody Construct\u003c\/td\u003e\n\u003ctd\u003eNot Specified\u003c\/td\u003e\n\u003ctd\u003eDeprioritized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSADA Platform\u003c\/td\u003e\n\u003ctd\u003eOMBLASTYS (omburtamab)\u003c\/td\u003e\n\u003ctd\u003eB7-H3 expressing tumors\u003c\/td\u003e\n\u003ctd\u003eRegistration-stage candidate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's overall financial structure as of recent filings includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and Cash Equivalents as of December 31, 2024: \u003cstrong\u003e$67.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated Total Annual Cash Investment for Full Year 2025: between \u003cstrong\u003e$25 million\u003c\/strong\u003e and \u003cstrong\u003e$30 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTrailing Twelve Month Revenue as of June 30, 2025: \u003cstrong\u003e$85.4M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eY-mAbs Therapeutics, Inc. (YMAB) - VRIO Analysis: 7. Expertise in GD2 Target Antigen\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nDANYELZA net product sales for the third quarter ended September 30, 2023, were \u003cstrong\u003e$20.0 million\u003c\/strong\u003e, representing \u003cstrong\u003e59%\u003c\/strong\u003e year-over-year growth. DANYELZA U.S. net product revenues for the quarter ended September 30, 2024, were \u003cstrong\u003e$15.3 million\u003c\/strong\u003e. Trial 1001 (GD2-SADA) Part A completion demonstrated safety and targeted conjugation with \u003cstrong\u003e177Lu-DOTA\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eBridge study (Part 2A) initiation planned for 1H \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePart B of Trial 1001 anticipated in early \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nExclusive license from Memorial Sloan Kettering Cancer Center (MSK) for SADA technology. DANYELZA is an FDA-approved product targeting GD2.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDANYELZA Net Product Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDANYELZA U.S. Patent Extension\u003c\/td\u003e\n\u003ctd\u003eThrough February \u003cstrong\u003e2034\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePrimary Patent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGD2-SADA Trial Phase 1 Part A Status\u003c\/td\u003e\n\u003ctd\u003eCompleted\u003c\/td\u003e\n\u003ctd\u003eTrial 1001\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGD2-SADA Next Study Initiation\u003c\/td\u003e\n\u003ctd\u003eEarly \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBridge Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe expertise is built through clinical trial execution, with Part A of Trial 1001 completed.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nExpertise embedded in the DANYELZA commercial unit and the Radiopharmaceuticals unit (Trial 1001).\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nPrimary DANYELZA U.S. patent extension through February \u003cstrong\u003e2034\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eY-mAbs Therapeutics, Inc. (YMAB) - VRIO Analysis: 8. Dual Business Unit Structure\n\u003c\/h2\u003e\n\u003cp\u003eThe January 2025 realignment into dedicated DANYELZA and Radiopharmaceuticals units allows for clearer focus and resource allocation for both commercial needs and pipeline advancement. The DANYELZA unit focuses on the FDA-approved treatment for relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. The Radiopharmaceuticals unit focuses on the novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA PRIT”) platform, which had preliminary Part A data from the GD2-SADA Phase 1 trial showing dosing of 21 patients across six sites with good tolerability, with data presentation expected in Q2 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial\/Operational Metric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreliminary Estimated Total Net Revenue\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$88 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eYear ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreliminary Cash, Cash Equivalents and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$67.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Total Revenues Guidance\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e$75 million\u003c\/strong\u003e and \u003cstrong\u003e$90 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Total Operating Costs and Expenses (ex-COGS) Guidance\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e$116 million\u003c\/strong\u003e and \u003cstrong\u003e$121 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Total Annual Cash Investment Guidance\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e$25 million\u003c\/strong\u003e and \u003cstrong\u003e$30 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce Reduction\u003c\/td\u003e\n\u003ctd\u003eUp to approximately \u003cstrong\u003e13%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eJanuary 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe realignment is intended to optimize resource allocation, supporting the commercial growth of DANYELZA while advancing the SADA PRIT platform. The DANYELZA unit benefits from its established position as the only FDA-approved treatment for high-risk relapsed\/refractory neuroblastoma.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDANYELZA U.S. net product revenues for Q1 2025 were \u003cstrong\u003e$13.4 million\u003c\/strong\u003e, a decrease of \u003cstrong\u003e28%\u003c\/strong\u003e from Q1 2024.\u003c\/li\u003e\n\u003cli\u003eDANYELZA Ex-U.S. net product revenues for Q1 2025 were \u003cstrong\u003e$7.5 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e$6.7 million\u003c\/strong\u003e from Q1 2024.\u003c\/li\u003e\n\u003cli\u003eTotal DANYELZA net product revenues for Q1 2025 were \u003cstrong\u003e$20.9 million\u003c\/strong\u003e, an \u003cstrong\u003e8%\u003c\/strong\u003e increase over Q1 2024.\u003c\/li\u003e\n\u003cli\u003eAs of December 31, 2024, DANYELZA was delivered to \u003cstrong\u003e69 centers\u003c\/strong\u003e across the U.S., with \u003cstrong\u003e11 new accounts\u003c\/strong\u003e added in 2024.\u003c\/li\u003e\n\u003cli\u003eAn upfront payment of \u003cstrong\u003e$2.0 million\u003c\/strong\u003e was received in Q4 2024 for the Japan license, with potential milestones up to \u003cstrong\u003e$31.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow. Reorganizing is a common management tool, not inherently rare.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow. Any competitor can restructure their internal teams.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh. This structure is designed to optimize exploitation of their current assets and future pipeline, showing management intent, evidenced by the appointment of a dedicated Senior Vice President, Head of DANYELZA Business Unit.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary. Its advantage relies on the execution within the new structure, not the structure itself.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eY-mAbs Therapeutics, Inc. (YMAB) - VRIO Analysis: 9. Advanced Clinical Trial Execution Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eVRIO Analysis Component: 9. Advanced Clinical Trial Execution Capability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eProven ability to move novel agents into human trials, evidenced by dosing the first patient in Trial \u003cstrong\u003e1201\u003c\/strong\u003e (NHL) in \u003cstrong\u003eQ1 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. Successfully initiating complex Phase 1 trials, especially in novel modalities like PRIT, is a significant operational skill.\u003c\/p\u003e\n\u003cp\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eDifficult. It requires established relationships with clinical sites and regulatory bodies.\u003c\/p\u003e\n\u003cp\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. The R\u0026amp;D team is actively driving the SADA platform forward, which is crucial for long-term value creation.\u003c\/p\u003e\n\u003cp\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. A reliable, experienced clinical development team is a core organizational asset in biotech.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$62.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial 1201 (CD38-SADA) First Patient Dosed\u003c\/td\u003e\n\u003ctd\u003eConfirmed\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial 1001 (GD2-SADA) Patients Dosed to Date (Part A)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJanuary 10, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 Total Expected Revenues Guidance Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$75 million\u003c\/strong\u003e to \u003cstrong\u003e$90 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Total Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSensitivity Analysis on \u003cstrong\u003e$62.3 million\u003c\/strong\u003e Cash Position based on a \u003cstrong\u003e10%\u003c\/strong\u003e drop in projected 2026 DANYELZA revenue:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e10% Drop Amount on Cash Position:\u003c\/strong\u003e \u003cstrong\u003e$6.23 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypothetical Post-Drop Cash Position:\u003c\/strong\u003e \u003cstrong\u003e$56.07 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSupporting Clinical Execution Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrial 1201 is designed to investigate the pretargeted delivery of the CD38-SADA protein followed by a radioactive \u003cstrong\u003e177Lu-DOTA\u003c\/strong\u003e payload.\u003c\/li\u003e\n\u003cli\u003ePart A of Trial 1001 demonstrated the pre-targeting approach to be well-tolerated with no dose-limiting toxicities (DLTs) reported.\u003c\/li\u003e\n\u003cli\u003eThe Company established two business units in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e to accelerate clinical development and optimize DANYELZA commercial potential.\u003c\/li\u003e\n\u003cli\u003eThe Company plans to share data from Part A of Trial 1001 in the \u003cstrong\u003esecond quarter of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516286754965,"sku":"ymab-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ymab-vrio-analysis.png?v=1740233255","url":"https:\/\/dcf-model.com\/pt\/products\/ymab-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}